The Ultimate Guide to Women's Sexual Health, Hormone Replacement Therapy (HRT) & Menopause

TL;DR

Dr. Rachel Rubin explains how hormone fluctuations drive UTIs, pelvic issues, and sexual dysfunction — and why cheap vaginal estrogen, long suppressed by false FDA labels, fixes most of it.

Key Points

• 1.Sexual medicine is a neglected specialty with dangerous knowledge gaps. The word 'clitoris' doesn't appear in what a gynecologist must know to graduate training in 2026, leaving women without knowledgeable providers for sexual health issues.
• 2.Women are routinely gaslit by doctors about sexual health symptoms. Common dismissals include 'drink a glass of wine for low libido,' 'just have more sex if it hurts,' and 'that part of your life is over now.'
• 3.Hormones follow a precise lifecycle every woman should understand. Estrogen ranges from ~50 at menstruation to ~150–300 at ovulation, surges to 3,000 during pregnancy, then crashes to near zero postpartum — each shift carrying physical consequences.
• 4.Breastfeeding is a form of menopause. When estrogen crashes from 3,000 to zero after birth, women experience hot flashes, brain fog, vaginal dryness, and increased UTI risk for the entire breastfeeding period.
• 5.Testosterone decline starts around age 35, not at menopause. This age-related drop — worsened by birth control pills and spironolactone — causes low libido, increased UTI risk, and pain with sex before perimenopause even begins.
• 6.GSM (Genital Urinary Syndrome of Menopause) affects women of all ages, not just menopausal women. Birth control pills suppress testosterone and ovarian function, altering vaginal pH and microbiome, which is why sexually active women in their 20s get chronic UTIs.
• 7.Vaginal hormones prevent UTIs by more than half and have been known since the 1970s. Research published in the New England Journal in the 1990s confirmed this; Dr. Rubin's team calculated vaginal hormones could save Medicare $6–22 billion annually.
• 8.False FDA box labels on hormone products blocked life-saving treatment for decades. Labels falsely stated estrogen causes stroke, blood clots, heart attacks, and probable dementia — none of which is supported by data for vaginal formulations.
• 9.On February 12, 2026 — Dr. Rubin's mother's birthday — the FDA officially removed the false warning labels. This followed years of advocacy, a 5-minute FDA commissioner testimony, and a November 2025 announcement at Health and Human Services.
• 10.Vaginal estrogen is available in multiple affordable forms for $7–13/month. Options include estradiol cream (~$13/tube, lasts 2.5 months), a 10-microgram suppository inserted twice weekly, or an Estring ring replaced every 3 months for patients with dexterity or dementia issues.
• 11.Vaginal hormones do not raise systemic estrogen levels meaningfully. A 70-year-old woman with zero estrogen who uses vaginal estrogen will only blip to ~20 for a few hours — less than the average man's resting estrogen of 25 — making it safe for all patients including breast cancer survivors.
• 12.A study of 50,000 women with active breast cancer found those who took vaginal estrogen died less. There is no data showing harm from vaginal hormones, and observational studies also show fewer heart attacks and strokes in users.
• 13.Hormonal IUDs (like Mirena) avoid the UTI-causing problem of birth control pills. Unlike pills that shut down ovaries and eliminate testosterone, the Mirena releases only micro-dosed progestin locally, allowing the ovaries to keep producing estrogen and testosterone.
• 14.Dr. Rubin personally fought ICU staff, pharmacists, and nurses to get her dying mother vaginal estrogen. Every level — doctors, pharmacy, nurses — cited the false box label as reason to refuse; she overcame each barrier while her father and brother advocated twice weekly for the treatment during a 6-month ICU stay.
• 15.Vaginal pH strips available on Amazon can help anyone self-monitor hormonal vaginal health. A pH of 4.5 or below (yellow/light green on the strip) indicates a healthy acidic environment; a high pH (dark blue) signals disrupted microbiome and UTI risk, prompting consideration of vaginal hormone therapy.**